Zevra Therapeutics, Inc.
ZVRA
$9.98
-$0.21-2.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 178.88% | 139.40% | 103.96% | -86.01% | -129.13% |
| Total Depreciation and Amortization | -36.55% | -3.40% | 65.24% | 160.18% | 535.09% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -270.18% | -322.93% | -1,234.69% | 1,364.93% | 551.54% |
| Change in Net Operating Assets | -268.63% | -399.68% | -644.02% | -1,000.48% | -222.25% |
| Cash from Operations | 97.71% | 66.42% | 17.56% | -35.19% | -107.74% |
| Capital Expenditure | -- | -1,102.78% | -27.87% | 62.92% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 183.54% | -47.86% | -222.72% | -157.67% | -266.54% |
| Cash from Investing | 181.80% | 303.59% | 25.29% | -276.57% | -27.44% |
| Total Debt Issued | -- | -100.00% | -100.00% | 95.21% | 37.51% |
| Total Debt Repaid | 99.14% | 99.22% | 99.22% | -790.91% | -138.29% |
| Issuance of Common Stock | -81.51% | -85.27% | 777.42% | 802.00% | 963.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 100.00% | -- | -- |
| Cash from Financing | -85.31% | -88.05% | 43.38% | 146.77% | 188.46% |
| Foreign Exchange rate Adjustments | -93.83% | 673.48% | -10.56% | 292.42% | 931.82% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 408.95% | -96.29% | 131.38% | -306.48% | 58.67% |